Invicro Appoints Dr. Joseph Krueger as Vice President, Research and Applications for Advanced Pathology Services

BOSTON–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/biomarkers?src=hash” target=”_blank”gt;#biomarkerslt;/agt;–Invicro LLC, a Konica Minolta company and a leading provider of imaging
services and software for research and drug development, today announced
the hiring of Dr. Joseph Krueger as Vice President, Research and
Applications for Advanced Pathology Services.

Dr. Krueger brings more than 15 years of in vivo and ex vivo experience
in evaluating disease, PK/PD, efficacy and biomarker hypotheses for drug
development. Dr. Krueger will drive Invicro’s tissue biomarker
application strategy and development activity to support pharmaceutical
and biotech sponsors.

“Joe brings a wealth of knowledge and experience in cancer biology and
computational pathology to the organization,” said Dr. Kenneth Bloom,
Chief Medical Officer, Advanced Pathology & Genomics Services for
Invicro. “We are very excited that he has joined our leadership team,
working to help our clients improve precision medicine.”

Prior to joining Invicro, Dr. Krueger was Chief Science Officer at
Flagship Biosciences Inc., where he led the R&D and Scientific efforts
in applying novel quantitative tissue image analysis approaches to
immuno-oncology and rare diseases to support drug and companion
diagnostic development. Prior to Flagship Biosciences, he served in
senior scientific roles in oncology drug development for OSI
Pharmaceuticals in Boulder, CO and Pfizer in Andover, MA.

“I am looking forward to help expand the growth and innovation of
Invicro’s Advanced Pathology Services business, by leveraging the
synergies of Invicro’s market leading ex vivo imaging capabilities, such
as Cryo-Fluorescence Tomography (CFT) and Konica-Minolta’s unique
Phosphor Integrated Dot (PID) technology, “stated Dr. Krueger. “It will
be exciting to help develop novel approaches with high resolution and
sensitivity that allow the evaluation of drugs and biomarkers in tissue,
which can accelerate drug development and bring groundbreaking precision
medicine methods to patients.”

Dr. Krueger did his postdoctoral fellowship at The Scripps Research
Institute and UC San Diego after completing his Ph.D. in Cancer Biology
at Wayne State University in Detroit, MI.

About Invicro
Headquartered in Boston, MA, Invicro was
founded in 2008 with the mission of improving the role and function of
imaging in translational drug discovery and development across all
therapeutic areas. Today, Invicro’s multi-disciplinary team provides
solutions to pharmaceutical and biotech companies across all stages of
the drug development pipeline (Phase 0-IV), all imaging modalities and
all therapeutic areas, including neurology, oncology, cardiology, and
pulmonary. Invicro’s quantitative biomarker services, advanced analytics
and AI tools, and clinical operational services are backed by Invicro’s
industry-leading software informatics platforms, VivoQuant® and iPACS®.

As part of the Konica Minolta precision medicine organization and with
their sister company Ambry Genetics, Invicro develops and leverages the
latest approaches in quantitative biomarkers including imaging,
quantitative pathology and genomics. For more information, visit www.invicro.com.

About Konica Minolta
Konica Minolta, Inc. (Konica Minolta)
is a global digital technology company with core strengths in imaging
and data analysis, optics, materials, and nano-fabrication. Through
innovation, Konica Minolta creates products and digital solutions for
the betterment of business and society—today and for generations to
come. Across its Business Technologies, Healthcare, and
Industrial-facing businesses, the company aspires to be an Integral
Value Provider that applies the full range of its expertise to offer
comprehensive solutions to the customer’s most pressing problems, works
with the partners to ensure the solutions are sustainable, anticipates
and addresses tomorrow’s issues, and tailors each solution to meet the
unique and specific needs of its valued customers. Leveraging these
capabilities, Konica Minolta contributes to productivity improvement and
workflow change for its customers and provides leading-edge service
solutions in the IoT era. Headquartered in Tokyo and with operations in
more than 50 countries, Konica Minolta has more than 43,000 employees
serving approximately two million customers in over 150 countries.
Konica Minolta is listed on the Tokyo Stock Exchange, (TSE4902). For
further information, visit: https://www.konicaminolta.com/.

Contacts

Amanda Harrell
VP, Global Marketing
[email protected]

error: Content is protected !!